Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
B lymphocyte chemoattractant, independently cloned and named Angie, is a CXC chemokine strongly expressed in the follicles of the spleen, lymph nodes, and Peyer's patches. Additionally we are shipping CXCL13 Proteins (40) and CXCL13 Kits (33) and many more products for this protein.
Showing 10 out of 114 products:
Human Monoclonal CXCL13 Primary Antibody for ELISA (Capture), FACS - ABIN4899778
Klimatcheva, Pandina, Reilly, Torno, Bussler, Scrivens, Jonason, Mallow, Doherty, Paris, Smith, Zauderer: CXCL13 antibody for the treatment of autoimmune disorders. in BMC immunology 2015
Show all 6 references for 4899778
Human Polyclonal CXCL13 Primary Antibody for IF (p), IHC (p) - ABIN741960
Pei, Zeng, Han, Liao, Zhou, Li, Zhang, Liu, Zhang, Liu, Yao, Xu: Renal interstitial infiltration and tertiary lymphoid organ neogenesis in IgA nephropathy. in Clinical journal of the American Society of Nephrology : CJASN 2014
Show all 4 references for 741960
Mouse (Murine) Polyclonal CXCL13 Primary Antibody for IF (p), IHC (p) - ABIN706691
Siepert, Brösel, Vogt, Ahrlich, Schmitt-Knosalla, Loddenkemper, Kühl, Baumgrass, Gerstmayer, Tomiuk, Tiedge, Viklický, Brabcova, Nizze, Lehmann, Volk, Sawitzki: Mechanisms and Rescue Strategies of Calcineurin Inhibitor Mediated Tolerance Abrogation Induced by Anti-CD4 mAb Treatment. in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013
Show all 3 references for 706691
Human Monoclonal CXCL13 Primary Antibody for FACS - ABIN4896649
Kobayashi, Watanabe, Suzuki, Furu, Ito, Ito, Matsuda, Yoshitomi: TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells. in European journal of immunology 2016
Show all 2 references for 4896649
Human Polyclonal CXCL13 Primary Antibody for IF (p) - ABIN892772
Nakamura, Ito, Kobayashi, Herndon, Suzuki: Orosomucoid 1 drives opportunistic infections through the polarization of monocytes to the M2b phenotype. in Cytokine 2015
High glucose could inhibit osteogenic differentiation of mesenchymal stem cells by lncRNA AK028326 mediated down-regulation of CXCL13 expression.
Data demonstrate that CXCL13 is not essential in mounting effective peripheral humoral responses, but specifically promotes CNS accumulation of differentiated B cells.
overexpression of CXCL13 is associated with myasthenia gravis.
Deficiency in Cxcl13 or its receptor, Cxcr5 (show CXCR5 Antibodies), significantly attenuated benzo(a)pyrene-induced lung cancer in mice, demonstrating CXCL13's critical role in polycyclic aromatic hydrocarbon-induced lung carcinogenesis.
Blockade of CXCL13 significantly reduced urine protein, serum creatinine, and dramatically attenuated renal pathology injury in lupus nephritis in mice.
Results from this study suggest blockade of CXCL13 and BAFFR (show TNFRSF13C Antibodies) together may be an effective therapeutic strategy in preventing salivary hypofunction and reducing autoantibody titers and sialadenitis in patients with Sjogren's syndrome
findings reveal a neuronal/astrocytic interaction in the spinal cord by which neuronally produced CXCL13 activates astrocytes via CXCR5 (show CXCR5 Antibodies) to facilitate neuropathic pain.
Study reports a novel role of AK141205/CXCL13 as a regulator of osteogenic growth peptide-induced osteogenic differentiation of smooth muscle cells.
Data indicate that CXC chemokine (show CXCL12 Antibodies) CXCL13-responsive late transitional B cells are the initiating subset for the positive feedback loop.
Study demonstrates that microglia are an important source of CXCL13 production in the acutely inflamed brain, and in vitro experiments confirm that type-I IFN selectively inhibits microglial production of CXCL13 in a dose-dependent manner
CCL21 (show CCL21 Antibodies) and CXCL13 levels are increased in the minor salivary glands of patients with Sjogren's syndrome.
we demonstrate that PKCepsilon (show PRKCE Antibodies) cooperates with the loss of the tumor suppressor Pten (show PTEN Antibodies) for the development of prostate cancer in a mouse model. Mechanistic analysis revealed that PKCe (show PRKCE Antibodies) overexpression and Pten (show PTEN Antibodies) loss individually and synergistically upregulate the production of the chemokine (show CCL1 Antibodies) CXCL13, which involves the transcriptional activation of the CXCL13 gene
During remission, serum CXCL13 and BAFF (show TNFSF13B Antibodies) levels have not decreased to normal in neuromyelitis optica patients, and B-cell-related autoimmune response persists. Immunosuppressive therapy decreased serum BAFF (show TNFSF13B Antibodies) levels, but did not affect CXCL13 expression.
This study suggested that increased serum levels of CXCL13 might be involved in renal ectopic lymphoid tissue (ELT)formation and renal impairment process in lupus nephritis.
CXCL13 mRNA expression and protein levels were significantly up-regulated in the brain from temporal lobe epilepsy patients.
CXCL13 could be a potential biomarker for predicting recurrence in HBV-related hepatocellular carcinoma patients after hepatectomy.
was overexpressed in pulmonary vascular lesions of patients with IPAH and CTEPH, and increased serum concentrations were found in patients with IPAH and CTEPH, suggesting a potential pathogenic role of CXCL13 in both diseases.
Findings suggest the potential use of chemokine (show CCL1 Antibodies) CXCL13 as a plasma biomarker of germinal centers (GCs (show GCLC Antibodies)) activity in vaccine trials and other clinical settings.
Aqueous humor concentration of CXCL13 is correlated with subfoveal choroidal thickness in normal subjects.
Serum CXCL10 (show CXCL10 Antibodies) and CXCL13 levels may serve as clinical markers and contribute to the inflammatory response, especially skin manifestations thereof, in adult-onset Still's disease
B lymphocyte chemoattractant, independently cloned and named Angie, is a CXC chemokine strongly expressed in the follicles of the spleen, lymph nodes, and Peyer's patches. It preferentially promotes the migration of B lymphocytes (compared to T cells and macrophages), apparently by stimulating calcium influx into, and chemotaxis of, cells expressing Burkitt's lymphoma receptor 1 (BLR-1). It may therefore function in the homing of B lymphocytes to follicles.
C-X-C motif chemokine 13
, B lymphocyte chemoattractant
, CXC chemokine BLC
, small inducible cytokine subfamily B (Cys-X-Cys), member 13
, small-inducible cytokine B13
, B-cell chemoattractant
, B-cell-attracting chemokine 1
, B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1)
, B-lymphocyte chemoattractant
, b cell-attracting chemokine 1
, b lymphocyte chemoattractant
, chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)
, small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cell chemoattractant)